$MDGL News

Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

Madrigal Pharma Announces New Analyses Of Phase 3 Data And Real-World Evidence Demonstrating Rezdiffra Reduced Markers Of Cardiovascular And Liver-Related Risk In Patients With MASH

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

Truist Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $709

A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales Growth

Madrigal Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $578

Evercore ISI Group Maintains Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $649

Madrigal Pharmaceuticals Q1 Earnings Call Highlights

Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Madrigal (MDGL) Q1 2026 Earnings Transcript

Madrigal’s (MDGL) MASH Strategy Reiinforced By Rezdiffra Sales Growth and Pipeline Expansion

Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Dip Despite Q1 2026 Earnings Beat and 127% Rezdiffra Revenue Growth

Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call

HC Wainwright & Co. Reiterates Buy on Madrigal Pharmaceuticals, Maintains $620 Price Target

Madrigal Pharmaceuticals Q1 EPS $(3.25) Beats $(3.60) Estimate, Sales $311.337M Beat $302.268M Estimate